Key facts
- Superbranche’s last known valuation is $9.5M (Jan 2023).
- It has raised $15.3M; the latest was Later Stage VC ($13.4M) in Feb 2025.
- Notable investors include Capital Grand Est, Alsace Business Angels, La Synapse, Quest for Health, SEMIA Incubateur d' Alsace.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Superbranche
- ·The full record, as it builds
Funding rounds
No funding rounds for Superbranche are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Superbranche
Developer of therapeutic and diagnostic applications designed for accessibility and detection of the tumor beforehand. The company's platform brings targeted diagnostic and image-guided therapy nanomaterials to clinics based on its proprietary technology, enabling patients to detect and treat metastases early.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2019
- Employees
- 10
- Website
- superbranche.com/
- Ownership
- Privately Held (backing)
Superbranche doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Superbranche shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Superbranche in its N-PORT filings yet. We sweep new filings monthly.